Is Sclerostin Glycoprotein a Suitable Biomarker for Equine Osteochondrosis?
Authors: Mendoza Luis, Franck Thierry, Lejeune Jean-Philippe, Caudron Isabelle, Detilleux Johann, Deliège Brigitte, Serteyn Didier
Journal: Journal of equine veterinary science
Summary
# Editorial Summary: Sclerostin as a Biomarker for Equine Osteochondrosis Osteochondrosis involves a complex interplay of growth rates, nutrition, endocrine function, and biomechanics, with mounting evidence suggesting the Wnt signaling pathway—regulated partly by sclerostin—may contribute to disease development. Researchers measured blood sclerostin concentrations in affected and healthy horses of various ages, using linear and logistic regression to determine whether circulating sclerostin levels correlated with OC presence, progression, or lesion healing. Whilst a significant age-related relationship with sclerostin was confirmed in both healthy and OC-affected cohorts, no meaningful association emerged between sclerostin concentration and either disease development or spontaneous recovery of existing lesions. These findings suggest that despite sclerostin's theoretical involvement in OC pathogenesis through Wnt pathway regulation, peripheral blood concentrations lack the sensitivity or specificity needed for clinical biomarker application. The authors recommend further investigation into sclerostin's role in equine bone homeostasis and skeletal metabolism before pursuing it as a diagnostic tool, highlighting the need for more sophisticated approaches to understanding OC's multifactorial aetiology.
Read the full abstract on PubMed
Practical Takeaways
- •Sclerostin blood testing should not be used clinically to diagnose, predict, or monitor osteochondrosis in horses
- •Age-related changes in sclerostin levels indicate it reflects normal bone metabolism rather than OC-specific pathology
- •Further research is needed to understand sclerostin's role in equine bone homeostasis and whether other biomarkers may be more useful for OC assessment
Key Findings
- •A significant relationship was found between age and sclerostin blood concentrations in both OC-affected and healthy horses
- •No significant relationship was found between sclerostin concentration and either risk of developing OC or recovery of existing lesions
- •Sclerostin is not suitable as a biomarker for osteochondrosis disease despite its theoretical involvement in the Wnt signaling pathway